IDEXX Laboratories Inc
NASDAQ:IDXX

  • LAST PRICE
    473.8850
  • TODAY'S CHANGE (%)
    -18.8750 (-3.8305%)
  • Bid / Lots
    473.1800/ 4
  • Ask / Lots
    474.5400/ 4
  • Open / Previous Close
    473.0000 / 492.7600
  • Day Range
    462.0000
    485.0000
  • 52 Week Range
    372.5000
    583.3900
  • Volume
    390,954

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

      Show headlines and story abstract

    • 5 hours ago by MT Newswires
      Companies Mentioned: IDXX
      07:10 AM EDT, 05/01/2024 (MT Newswires) -- IDEXX Laboratories (IDXX) reported Q1 earnings Wednesday of $2.81 per diluted share, up from $2.55 a year earlier. Analysts polled by Capital IQ expected $2.67. Revenue for the quarter ended March 31 was $...

    • 5 hours ago by Dow Jones
      Companies Mentioned: IDXX

      By Rob Curran

      Idexx Laboratories posted first-quarter net income growth but cut its projection for 2024 revenue growth amid signs that the pet-care boom that began during the pandemic may be easing.

    • 6 hours ago by MT Newswires
      Companies Mentioned: IDXX
      06:38 AM EDT, 05/01/2024 (MT Newswires) -- ...

    • 6 hours ago by Business Wire
      Companies Mentioned: IDXX

      IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results.

      First Quarter Results

      The Company reports revenues of $964 million for the first quarter of 2024, an increase of 7% as reported and organic, driven by Companion Animal Group ("CAG") growth of 7% as reported and organic, and Water revenue growth of 11% as reported and organic. Overall IDEXX revenue gains were net of an estimated 0.5% - 1% negative growth rate impact from severe U.S. weather in January. CAG Diagnostics recurring revenue growth of 7% as reported and organic was supported by sustained benefits from IDEXX execution drivers. 8% global premium instrument placement growth and continued high customer retention levels supported 11% annual growth in IDEXX's global premium instrument installed base. High demand for IDEXX solutions drove veterinary software, services and diagnostic imaging systems revenue growth of 12% as reported, including benefits from a software and data platform acquisition completed in the period, and 8% organic growth, reflecting high recurring revenue growth and continued momentum in cloud-based software placements.

    • 6 hours ago by Dow Jones
      Companies Mentioned: IDXX
      repurchases $ 550.90 $ -- Average cost per share -- employee surrenders $ 560.56 $ 503.65 Average cost per share -- total $ 551.45 $ 503.65 -------------------------------------------- --- -------- -------

Peers Headlines